Drug intelligence / Profile preview

APG-3526

Development stage: Preclinical
Lead developer: Ascentage Pharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

APG-3526 is an investigational **small-molecule** anticancer agent developed by **Ascentage Pharma** that selectively inhibits **myeloid cell leukemia 1**. It binds MCL-1 with nanomolar potency and disrupts the **MCL-1:BIM** protein-protein interaction, thereby releasing pro-apoptotic BIM and triggering mitochondrial apoptosis in tumor cells. Preclinical data described potent activity in MCL-1-dependent hematologic malignancy models, particularly multiple myeloma, and the program has been positioned for development in hematologic cancers and selected solid tumors.

Targets

MCL1 (Myeloid cell leukemia sequence 1)

Beyond the preview

Go deeper on APG-3526.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APG-3526.

Explore the full profile